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ABSTRACT
Background: Screening for colorectal cancer (CRC)
with guaiac-based faecal occult-blood test (FOBT) has
been reported to reduce CRC mortality in randomised
trials in the 1990s, but not in routine screening, so far.
In Finland, a large randomised study on biennial FOB
screening for CRC was gradually nested as part of the
routine health services from 2004. We evaluate the
effectiveness of screening as a public health policy in
the largest population so far reported.
Methods: We randomly allocated (1:1) men and
women aged 60–69 years to those invited for
screening and those not invited (controls), between
2004 and 2012. This resulted in 180 210 subjects in
the screening arm and 180 282 in the control arm. In
2012, the programme covered 43% of the target age
population in Finland.
Results: The median follow-up time was 4.5 years
(maximum 8.3 years), with a total of 1.6 million
person-years. The CRC incidence rate ratio between the
screening and control arm was 1.11 (95% CI 1.01 to
1.23). The mortality rate ratio from CRC between the
screening and control arm was 1.04 (0.84 to 1.28),
respectively. The CRC mortality risk ratio was 0.88
(0.66 to 1.16) and 1.33 (0.94 to 1.87) in males and
females, respectively.
Conclusions: We did not find any effect in a
randomised health services study of FOBT screening
on CRC mortality. The substantial effect difference
between males and females is inconsistent with the
evidence from randomised clinical trials and with the
recommendations of several international
organisations. Even if our findings are still
inconclusive, they highlight the importance of
randomised evaluation when new health policies are
implemented.
Trial registration: 002_2010_august.
INTRODUCTION
Accumulated evidence from large rando-
mised trials1–6 has shown a mortality effect
of colorectal cancer (CRC) screening using
faecal occult-blood test (FOBT). The
average reduction in CRC mortality is esti-
mated to be 12%, varying from 10% to
21%, based on the most recent meta-
analysis.7 These trials suggest even a bigger
reduction in CRC mortality with annual
screening.1 2 In the ﬁrst report of the UK
study,3 with a median follow-up of 7.8 years,
the difference in CRC mortality between
screening and control arms was 15%, and
the effect began to emerge after 3–4 years
from study entry. In the follow-up of the
same study,4 with a 15-year screening
period and almost 15 years of follow-up
after the screening period, a 12% reduction
in CRC mortality was observed. In the US
trial,1 the biennial screening arm had a
Summary box
What is already known about this subject?
▸ Randomised trials with guaiac-based faecal
occult-blood test (FOBT) have been reported to
reduce colorectal cancer (CRC) mortality in the
1990s.
▸ The EU and the US both recommend screening
from 50 until 74 years of age.
▸ Evidence of the effectiveness of guaiac-based FOB
in screening as a part of routine health service
with unselected study subjects is missing.
What are the new findings?
▸ Our randomised health services study of FOBT
screening on CRC mortality found no effect.
▸ We observed a substantial effect difference
between males and females, still inconclusive
however.
How might it impact on clinical practice in
the foreseeable future?
▸ Re-evaluation of existing screening practices for
CRC with FOBT in current health service pro-
grammes might be needed.
▸ Before applying any new test as routine health
service a randomised evaluation of the effective-
ness is warranted.
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higher CRC mortality than the control arm, from 4–5
to 8–9 years after study entry, and, overall, a modest
6% reduction in CRC mortality was detected. In the
analysis of the same trial with 30 years of follow-up,2
14 years during the screening period and 16 years after
that, a 12% reduction in CRC mortality was observed. In
the Danish and Swedish trials, the difference in the
cumulative CRC mortality emerged at about 8 years of
follow-up or later.5 8 Results on CRC mortality with
repeated FOB-based testing have also been reported
from non-randomised studies in France9 (a 33% reduc-
tion) and Germany10 (a 34% reduction).
The US trial (Minnesota) with 30 years of follow-up
found a signiﬁcantly different reduction in CRC mortal-
ity between males and females in the biennial screening
arm, RR=0.63 (95% CI 0.48 to 0.82) and RR=0.92 (95%
CI 0.72 to 1.18), respectively.2 On the other hand, in the
UK trial, the reduction in CRC mortality with approxi-
mately 20 years of follow-up was similar in males
(RR=0.91, 95% CI 0.82 to 1.02) and females (RR=0.90,
0.80 to 1.01).4
Globally, 1.2 million new CRC cases are diagnosed and
600 000 deaths are due to CRC annually.11 Cancers of
the colon and rectum remain the third most common
(ranked by site speciﬁc incidence) in Finland. There
were 2904 new CRC cases (ICD-10 classiﬁcation: C18–
C21) in Finland of 5.42 million inhabitants and 1161
CRC deaths in 2012.12 In Finland, between 2001–2012,
CRC mortality has decreased annually on average by
1.5% per year in males and 0.7% per year in females.13
Effective tools for primary prevention are limited, and
preventive efforts have focused on the detection of CRC
in the early stages of the tumour growth process. CRC is
considered to develop via an adenoma to carcinoma
sequence.14 Effective screening results in detection of
adenomas and preclinical cancers and thereafter in
decreased CRC mortality. At the moment, the EU15 and
the US16 both recommend screening for CRC starting
from 50 until 74 years of age.
A new screening programme should allow unbiased
evaluation of the effectiveness in the target population.17
A service programme has more challenges than rando-
mised trials, and the expected effect is usually smaller
than that observed in randomised trials.18 19 Service pro-
grammes are run within the normal health care system
including more variation in the process and with limited
resources and often less devoted human resources as
compared to scientiﬁc trials. Thus, the real life applica-
tion, service programmes, should be evaluated rigorously
including randomisation. This is possible only during
the implementation period of the new screening pro-
gramme, with disease-speciﬁc mortality as the end
point.17
We report here the ﬁrst results on mortality of an indi-
vidually randomised community-based CRC screening
programme (a randomised health services (RHS) study)
with the FOB based biennial test among 360 000 men
and women in Finland.
METHODS
Study design
The Finnish population-based screening programme was
individually randomised (1:1) in the implementation
phase by region, gender and birth year to those to be
invited for screening (screening arm) and those not
invited (control arm), based on Central Population
Register (CPR) data and consent applied as carried out
in the Finnish health services. The target group
included men and women from 60 to 69 years of age.
Details of the study design have been reported
earlier.20 21 The working group of screening at the
Finnish Ministry of Social Affairs and Health decided
ﬁrst to recommend a 6-year implementation period with
random allocation of the population to be able to evalu-
ate the effects reliably. In 2009, due to low coverage of
the programme, the randomisation period was extended
up to the year 2014. Thus, the estimation of effectiveness
is needed for health policy planning, after the end of
the extended randomisation period. At this point we
need to take a decision on either to apply for continu-
ation of the implementation period or to apply for
closing the randomisation period.
In short, from 2004 until 2012, altogether 362 165
persons were individually randomised either to screen-
ing (181 080 subjects) or control (181 085 subjects) arm.
All individuals in the screening arm were invited if they
had a valid address available from the CPR. The present
study population covered approximately 43.5% (invitees
21.8%) of the whole Finnish target population aged 60–
69 years at the end of 2012.22
The CPR has a legislative mandate to collect records
on residents of Finland including a personal identiﬁca-
tion code that can be used to link data from various
health registers. The register also includes the name,
birth date and a valid home address; and dates of emi-
gration and death in case the person has moved outside
Finland or died, respectively. Statistics Finland receives
death certiﬁcates of all deaths and codes the ofﬁcial
cause of death nationally. The Finnish Cancer Registry
(FCR) collects national data on cancer cases since 1953
with high coverage, close to 99% for solid tumours.23
The personal identiﬁcation code is used to link people
between these registers.
Assessment of study subjects and end points
Subjects who died after the retrieving of the population
sample from the CPR but before or at the date of ran-
domisation were excluded (94 in total; 49 invitees and
45 controls) from analysis (ﬁgure 1). Similarly also we
excluded those who emigrated (in total 7; 4 invitees and
3 controls). Subjects who were diagnosed with CRC
before or at the date of the randomisation were also
excluded (1572; 817 invitees and 755 controls). In
January 2007, some controls (109 subjects) received a
screening invitation due to problems in the software—in
the activity itself these people were kept in the screening
arm. For the present analysis, these people were
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included in the original control arm. In the ﬁnal analysis
we had a total of 360 492 subjects (180 210 in the screen-
ing arm and 180 282 in the control arm).
Incident CRC cases and deaths from CRC were
retrieved by linkage with the FCR and deﬁned according
to the ICD-O-3 classiﬁcation topography codes C18.0–
C21.2 and C26.0 if malignant behaviour, excluding
lymphomas (morphology codes ≥9590) and anal epi-
dermoid cancers (topography C21.0–C21.2 and morph-
ology code 8070). Information about the vital status at
the end of 2012, including date of death and emigra-
tion, was received from the CPR, and cause of death was
obtained from Statistics Finland through record linkage
with the unique personal identiﬁcation number.
Our primary end point in the current study was death
from CRC deﬁned by the ofﬁcial classiﬁcation of death
by Statistics Finland. Death due to any cause was the end
point in assessing the excess (all-cause) mortality among
patients with CRC (diagnosed after the date of random-
isation). We deﬁne a screen-detected CRC event to be a
cancer diagnosed within 6 months from the screening
test. An interval cancer is one that is detected after the
6 month period from the screening test but before the
next screen.
Screening process
Those invited for screening every second year, were admi-
nistered the guaiac-based non-rehydrated FOBT at home
after receiving three test-cards (Hemoccult) and instruc-
tions by postal mail. A faecal sample was instructed to be
collected three times within 1 week of the ﬁrst sample by
obtaining two smears from different locations of the
faeces. Dietary restrictions consisted of avoiding raw
meat, blood and liver dishes 3 days before sample-taking
and during the time of sampling. Also, vitamin C supple-
ments with more than 250 mg of vitamin were not to be
used. Test cards were returned by mail to be analysed at
the national screening centre at Pirkanmaa Cancer
Society in Tampere. One central laboratory covered all of
Finland and samples were analysed within 14 days of
sample-taking. Results from testing were notiﬁed via
postal mail to all attenders. In case of blood in any of the
samples (test positive), a regional contact nurse was also
informed. The contact nurse interviewed (phone mostly)
the test-positive participant and thereafter organised a
full colonoscopy examination. Colonoscopies were per-
formed regionally either at the health centre, private
clinics or hospitals, by experienced physicians having
extensive training in colonoscopy (mostly specialised gas-
troenterologists). The overall compliance of colonoscopy
was 84% and the annual compliance varied from 81% to
90% by calendar year. Colonoscopies of controls and in
invitees not attending screening as well as those resulting
as interval cancers were performed by the same providers
as the screen induced ones.
Statistical analysis
Original sample size calculation was based on 90%
power and a 5% type I error if the true effect was 20%20
in CRC mortality. These assumptions implied that we
would need to accumulate 1.6 million person-years in
the current study. Incidence and mortality rates were
estimated by dividing the respective numbers of death
from any cause, from CRC and from causes other than
CRC, by the number of person-years. The number of
person-years is the sum of each subject’s time at risk. In
Figure 1 Flowchart of the number of subjects randomised, excluded and in the analysis dataset.
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the estimation of incidence, the time at risk was calcu-
lated from randomisation to CRC diagnosis, death, emi-
gration, or to the end of 2012, whichever came ﬁrst. In
estimation of the mortality, the time at risk was calcu-
lated from randomisation until death, emigration, or to
the end of 2012, whichever came ﬁrst. The ratios of the
mortality rates and of the excess mortality rates were esti-
mated within the intention-to-treat principle to measure
the effect of the service screening. Conﬁdence intervals
(CIs) were estimated assuming the observed number of
deaths to follow a Poisson probability law. The difference
in the effect of mortality from CRC between males and
females was tested using the Cox proportional hazards
model and the classical likelihood ratio test. Restricted
cubic spline functions24 25 with a time-dependent effect
of invitation were ﬁtted to individual-level follow-up data
for describing arm-speciﬁc CRC mortality rates (ie, the
hazard of death from CRC) and their ratio over
follow-up time. Cumulative proportion of deaths from
CRC was estimated in a competing risk setting using a
weighted empirical cumulative distribution function.26
The excess mortality rate was estimated by dividing the
excess number of deaths observed in patients with CRC
by the total number of person-years in each arm.27 28
Details of estimation of excess mortality rate and its vari-
ance using the delta method are described in online
supplementary appendix. When follow-up was started
1 year after randomisation in order to remove the
period with no potential effect of screening, our results
did not change and, thus, the results are presented with
full follow-up starting from the date of randomisation.
Ethics
The RHS study on implementation of CRC screening
was approved by the Ministry of Social Affairs and
Health in 2004 (STM/42/07/2004) and updated in
2010 by the ofﬁcial authority, the National Institute of
Health and Welfare (THL/619/5.05.00/2010). The
study has been registered in the registry for RHS studies
maintained by the Cancer Society of Finland (http://
www.cancer.ﬁ/rhs/002_2010_august/).
RESULTS
The background characteristics between the screening
and control arms were in balance (table 1). Approximately
20 000 subjects were assigned annually either to the
screening or the control arm resulting in 180 000 invitees
by the end of 2012 and a similar number of controls. The
median follow-up time in our study was 4.5 years (range
0.0–8.3), with 25% of subjects (approximately 90 000
subjects) with at least 6.5 years of follow-up. The longest
follow-up time was 8.3 years.
In all, close to 440 000 invitations were sent between
2004 and 2012, with an uptake of 68.8% (61.5% among
males and 76.0% among females; table 2). The propor-
tion of FOB positive tests was 3.6% of all tests (4.7%
among males and 2.7% among females). The propor-
tion of screen-detected CRCs was 42.7% of all CRCs
(41.7% among males and 43.9% in females) (table 2).
Colonoscopy was performed in 84% of screen positives.
Altogether, 73% out of the total number of 1.6 million
person-years were accumulated during the ﬁrst 4 years
after randomisation (table 3). The incidence rate of
CRC was higher in the screening arm compared to the
control arm: 112.4/100 000 person-years in the screen-
ing arm and 100.9/100 000 person years in the control
arm (table 3). The CRC incidence rate ratio between
the screening and control arm was 1.11 (95% CI 1.01 to
1.23). In both arms, the incidence rate of CRC was
higher in males (133.1/100 000 in the screening arm
and 120.8/100 000 in the control arm) than in females
(92.4 and 81.7/100 000). The CRC incidence rate ratio
for males was 1.10 (0.97, 1.25) and for females, 1.13
(0.98, 1.31).
The numbers of new CRC cases showed a substantial
difference in the ﬁrst 2-year interval after randomisation:
84 more people were diagnosed with CRC in the screen-
ing than in the control arm (table 4).
A total of 15 963 deaths occurred during the follow-up
(table 3), 8000 deaths in the screening arm and 7963 in
the control arm. We did not ﬁnd any difference between
study arms in overall mortality rate (rate ratio, RR, 1.00;
95% CI 0.97 to 1.04) or in mortality rate from other
Table 1 Numbers and proportions (%) of subjects aged 60–64 years and randomised for screening and control arms
according to calendar year, sex and study arm
Screening Control
Calendar year Men Women Total Men Women Total
2004 2132 (2.4) 2389 (2.6) 4521 (2.5) 2136 (2.4) 2377 (2.6) 4513 (2.5)
2005 11 581 (12.9) 11 853 (13.1) 23 434 (13.0) 11 578 (12.9) 11 872 (13.1) 23 450 (13.0)
2006 12 391 (13.8) 12 368 (13.7) 24 759 (13.7) 12 403 (13.8) 12 378 (13.7) 24 781 (13.7)
2007 10 685 (11.9) 10 691 (11.8) 21 376 (11.9) 10 689 (11.9) 10 694 (11.8) 21 383 (11.9)
2008 11 873 (13.2) 12 264 (13.6) 24 137 (13.4) 11 875 (13.2) 12 235 (13.5) 24 110 (13.4)
2009 12 036 (13.4) 12 153 (13.4) 24 189 (13.4) 12 078 (13.4) 12 141 (13.4) 24 219 (13.4)
2010 9919 (11.1) 9898 (10.9) 19 817 (11.0) 9946 (11.1) 9887 (10.9) 19 833 (11.0)
2011 8841 (9.9) 8807 (9.7) 17 648 (9.8) 8830 (9.8) 8815 (9.7) 17 645 (9.8)
2012 10 254 (11.4) 10 075 (11.1) 20 329 (11.3) 10 272 (11.4) 10 076 (11.1) 20 348 (11.3)
Total 89 712 (100) 90 498 (100) 180 210 (100) 89 807 (100) 90 475 (100) 180 282 (100)
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causes than CRC (RR 1.00; 0.97 to 1.04). The overall
mortality rate in screening and control arms was similar
in females (RR 1.00; 0.95 to 1.06) and in males (RR
1.01; 0.97 to 1.05). There was no difference between
screening and control arms in other cause mortality in
females (RR 0.99; 0.94 to 1.05) or in males (RR 1.01;
0.97 to 1.05). CRC was the cause of death for 170
persons in the screening arm and 164 persons in the
control arm (table 3). We did not ﬁnd any difference in
CRC mortality rate between the screening and the
control arm (RR 1.04; 0.84 to 1.28). In males, the CRC
mortality rate ratio was 0.88 (0.66 to 1.16) and in
females, 1.33 (0.94 to 1.87). The interaction between
study arm and gender in CRC mortality rate was of bor-
derline signiﬁcance (p=0.06). The excess mortality rates
gave similar estimates: RR 1.05 (0.84 to 1.30) in males
and females combined, and 0.94 (0.71 to 1.24) in males
and 1.26 (0.88 to 1.80) in females. Figure 2 shows the
cumulative CRC mortality proportion per 100 000
persons in screening and control arms for up to
8.3 years from study entry. There was no difference in
cumulative CRC mortality between screening and
control arm. In females the cumulative CRC mortality in
the screening arm was consistently larger than in the
control arm, while in males cumulative CRC mortality in
the screening arm was smaller than in the control arm.
Smoothed CRC mortality rates and CRC mortality rate
ratios as a function of follow-up time for screening and
control arms by gender are shown in ﬁgure 3. There was
no consistent pattern in the rate ratios by sex and
follow-up time. The difference between the arms in the
overall numbers of CRC deaths was small; at most, three
deaths per 2 year interval (except early deaths in interval
0–2 years) (table 4).
DISCUSSION
Our community-based RHS study did not show any dif-
ference in CRC mortality between arms (RR=1.04).
Despite the estimated 12% (RR=0.88) reduction in CRC
mortality rate found in males and 33% (RR=1.33)
increase in females, neither of these rate ratios was statis-
tically signiﬁcant. The difference between males and
females in CRC mortality rate ratio was of borderline sig-
niﬁcance. Our estimates of the excess mortality rate due
to CRC were similar to the above results.
Our study is a RHS study in contrast to a scientiﬁc ran-
domised controlled trial (RCT). Major difference
between the two types of studies is in the origin of the
observations, they are either a by-product of a routine
activity (RHS) or they are speciﬁcally designed for a
research purpose (RCT). Therefore, RHS is particularis-
tic and based on routine health services, whereas the
objective of a RCT is abstract and general, that is, scien-
tiﬁc. Randomisation and timing are similar but ethics,
funding, blinding and several other aspects differ
between RHS and RCT.17
Based on information from the earlier RCTs,29 the
effect of screening in reducing CRC mortality is likely to
be observed after a longer follow-up than that in the
current study, with a median 4.5 years (maximum of
8.3 years) of follow-up. This is supported by the results of
Mandel et al,1 who found only a 6% reduction in CRC
mortality after 13 years of follow-up with biennial screen-
ing, and the reduction was 21% in a later analysis.2
Originally, our study was planned to ﬁnd a statistically sig-
niﬁcant reduction in CRC mortality if the true effect had
been 20%. According to the recent meta-analysis, the esti-
mate of the mortality effect was 15%.7 A longer follow-up
would reduce uncertainty in our effect estimate and
narrow the CI. Therefore, it is possible that the beneﬁcial
effect of biennial screening with FOBT on CRC mortality
emerges only after 6–10 years of follow-up.1
The excess mortality rate measures both the direct
and indirect mortality due to CRC.27 Unlike CRC mor-
tality, the excess mortality does not depend on the reli-
ability of classiﬁcation of deaths, as it compares all-cause
mortality in patients with CRC with that in comparable
CRC-free persons. Because the estimate of CRC mortal-
ity rate was similar to that of the excess mortality, the
non-existing screening effect is unlikely to be due to mis-
classiﬁcation of the causes of death.
The need for analysis of the screening effect at hand
was spelled out with the Ministry of Social Affairs and
Health in Finland, in an agreement on evaluation after
the implementation phase of the programme and
before making any decision on its future. The imple-
mentation phase of the screening programme was based
on gradual expansion in the ﬁrst 6 years (2004–2009)
and on follow-up of ﬁve more years (2010–2014).
Our study is a part of Finnish public health and there-
fore many factors differ compared to earlier screening
trials.1 3 In routine service screening, there is more vari-
ation in available resources (both human and material),
the population may be less motivated, and experts are
not as devoted and do not follow the guidelines as
strictly as in scientiﬁc trials. Despite the high compliance
(70%), selection among our study subjects cannot be
Table 2 Compliance to screening and test results by sex in 2004–2012
Colorectal cancers
Gender Invitations Screens (%) Positive tests (%) Screen detected (%) Other
Males 216 393 133 029 (61.5) 6215 (4.7) 220 (41.7) 305
Females 222 281 168 871 (76.0) 4528 (2.7) 166 (43.9) 212
Total 438 674 301 900 (68.8) 10 743 (3.6) 386 (42.7) 517
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Table 3 Descriptive and comparative statistics for colorectal cancer incidence and mortality, by study arm and sex
All Males Females
Screening Control Screening Control Screening Control
Number of persons 180 210 180 282 89 712 89 807 90 498 90 475
Person-years 805 480 805 693 395 614 395 851 409 866 409 843
Deaths
All causes 8000 7963 5486 5453 2514 2510
Colorectal cancer 170 164 93 106 77 58
Patients with colorectal cancer
Number of patients 903 811 525 477 378 334
Incidence rate per 100 000 person-years 112.4 100.9 133.1 120.8 92.4 81.7
Person-years 2285 1805 1318 1016 967 790
Deaths 202 190 123 127 79 63
Expected number of deaths* 25.0 21.1 18.6 15.7 6.4 5.5
Excess number of deaths† 177.0 168.9 104.4 111.3 72.6 57.5
CRC incidence rate ratio (95% CI) 1.11 (1.01 to 1.23) 1 1.10 (0.97 to 1.25) 1 1.13 (0.98 to 1.31) 1
Mortality rates per 100 000
All causes 993 988 1387 1378 613 612
Non-colorectal cancer causes 972 968 1363 1351 595 598
Colorectal cancer 21.1 20.4 23.5 26.8 18.8 14.2
Excess mortality due to CRC 21.7 21.0 26.4 28.1 17.7 14.0
Mortality rate ratios
All causes 1.00 (0.97 to 1.04) 1 1.01 (0.97 to 1.05) 1 1.00 (0.95 to 1.06) 1
Non-colorectal cancer causes 1.00 (0.97 to 1.04) 1 1.01 (0.97 to 1.05) 1 0.99 (0.94 to 1.05) 1
Colorectal cancer 1.04 (0.84 to 1.28) 1 0.88 (0.66 to 1.16) 1 1.33 (0.94 to 1.87) 1
Excess mortality due to CRC 1.05 (0.84 to 1.30) 1 0.94 (0.71 to 1.24) 1 1.26 (0.88 to 1.80) 1
*Calculated according to the mortality of colorectal cancer-free persons stratified by sex, age, calendar year, arm and participation status.
†The difference between the observed and the expected number of deaths.
CRC, colorectal cancer.
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ruled out. In randomised scientiﬁc trials, the eligibility
of study subjects is guaranteed either by inclusion or
exclusion criteria as part of the study protocol. These
selective processes also introduce a possibility for incom-
parability when the test is applied to an unselected
target population.
There is also substantial difference concerning various
patient and health services characteristics between the
old trials and the current study. Survival of patients with
CRC has improved substantially from the time of the
early clinical trials to the beginning of 2000, from 40%
to close to 60% in all Nordic countries,13 and a steady
improvement of 5-year survival from colon and rectal
cancer has been observed in developed countries.30 31
Such improvement in survival of the controls leads to a
smaller difference in CRC mortality between rando-
mised groups and thus lower statistical power to detect
it.
The uptake of screening was relatively high in our pro-
gramme. Usually, the uptake is lower in routine applica-
tion (RHS) than in controlled trials (RCT). In Finland,
the uptake was 69%. It was less than that reported from
the US trial (Minnesota Colon Cancer Control Study)1
(78%), but better than that of the Nottingham Study3
(60%). Therefore, it is not likely that our lack of signiﬁ-
cant effect can be explained by lower participation.
In the current study, the sensitivity of FOBT improved
after the ﬁrst years of screening.21 The most conclusive
data are provided by the longest follow-up. Unfortunately,
these data had, at the same time, the poorest sensitivity.
This indicates a learning curve. Uptake in the Bowel
Cancer Screening Program32 in England was 57% in the
ﬁrst round, 61% in the second and 66% in the third
Table 4 Number of persons alive at the beginning of four consecutive follow-up time intervals and numbers of person-years,
colorectal cancer cases and deaths from colorectal cancer, and from other causes, during each follow-up time interval, by sex
and arm
All Males Females
Follow-up interval Screening Control Screening Control Screening Control
Persons alive at the beginning of follow-up interval
[0, 2) 180 210 180 282 89 712 89 807 90 498 90 475
[2, 4) 139 696 139 765 68 865 68 950 70 831 70 815
[4, 6) 100 060 100 034 48 706 48 693 51 354 51 341
[6, 8.3) 60 993 61 022 29 537 29 566 31 456 31 456
Person-years
[0, 2) 335 031 335 127 166 096 166 222 168 935 168 905
[2, 4) 251 879 251 992 123 648 123 745 128 231 128 247
[4, 6) 157 381 157 374 76 607 76 603 80 774 80 771
[6, 8.3) 61 189 61 201 29 264 29 282 31 925 31 920
Colorectal cancer cases
[0, 2) 371 287 218 162 153 125
[2, 4) 259 264 148 167 111 97
[4, 6) 194 185 114 107 80 78
[6, 8.3) 79 75 45 41 34 34
Deaths from colorectal cancer
[0, 2) 42 35 27 21 15 14
[2, 4) 50 51 20 33 30 18
[4, 6) 49 52 23 33 26 19
[6, 8.3) 29 26 23 19 6 7
Deaths from other causes
[0, 2) 2815 2781 1965 1948 850 833
[2, 4) 2426 2417 1671 1669 755 748
[4, 6) 1787 1797 1239 1195 548 602
[6, 8.3) 802 804 518 535 284 269
Figure 2 Cumulative colorectal cancer mortality proportion
(per 100 000 persons) by study arm (screening arm with solid
line and control arm with dashed line) and sex.
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round. A similar increase in uptake by round was also
observed in our programme.33 The improved sensitivity
and better uptake both indicate a potential improvement
in the effect in the future.
The ideal design would have been to compare FOBT,
faecal immunochemical test (FIT) and no screening.
The reports on FIT positivity proportion vary from 4% to
10%,34 35 high for routine screening with colonoscopy in
screen positives. It is possible that FIT would have shown
a mortality reduction even at the same positivity propor-
tion threshold as our FOBT (3%), because in such a case
more individuals with bleeding had been identiﬁed. The
reason for bleeding is, however, unknown. There is no
direct evidence on improved effectiveness of FIT com-
pared to FOBT, for the time being.
Contamination of the control arm by wild screening is
likely to be small in Finland. CRC screening for average
risk individuals without symptoms is not common and
regular GP checking for healthy individuals is not a
common practice. Faecal occult blood tests are used
mainly in clinical settings for follow-up of bowel diseases
or as part of diagnostics, not in screening purposes. In
summary, the effectiveness of routine screening for CRC
with FOBT still remains open.
Several international bodies, including the American
Cancer Society29 and the EU,15 recommend routine
screening for CRC with FOBTs. The recommendations
are based on evidence from randomised studies,1 3 5 6 8
but they do not include the evaluation of the process as
part of the routine health service system. The Finnish
programme is consistent in process results and not sig-
niﬁcantly different in the mortality outcome with evi-
dence available so far.
The difference between males and females in the
effect on CRC mortality was of borderline signiﬁcance.
Three trials2 4 6 and two case–control studies9 10 reported
reduction in CRC mortality for males and females separ-
ately. The reduction in CRC mortality in males was
between 5% and 37%, and in females between 8% and
26%. In our study, the reduction in CRC mortality in
males (12%) is consistent with the previous studies.
However, we are concerned with the observed 33%
increase in CRC mortality in females, which has not
been reported by any of the other studies. Regarding
biennial FOBT, there is concern on poor sensitivity of
the guaiac FOBT in Finland, especially in women.21 36
Also, the Norwegian screening study on ﬂexible sigmoid-
oscopy and FOBT either combined or with ﬂexible
Figure 3 Smoothed colorectal cancer mortality rate (per 100 000 person-years) in the screening and control arm over follow-up
time, and ratio of the mortality rates by study arm and sex. Dotted lines show the limits of 95% CIs for the rate ratio.
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sigmoidoscopy alone, reported a different effect on mor-
tality between men and women37: screening was effective
in men (RR for CRC mortality 0.58, 95% CI 0.40 to 0.85)
but not in women (RR 0.91, 0.64 to 1.30) after a median
follow-up of 10.9 years. A similar effect in CRC mortality
was observed after adenoma removal in males and
females: the SMR for CRC was 0.86 (0.74 to 1.00) and
1.06 (0.93 to 1.22), respectively.38
There are different hypotheses as to why women may
not beneﬁt as much as men from screening with
FOBTs,2 including proportionally more adenomas and
CRCs in the proximal colon in men than in women, and
that the biology may be different (sessile serrated
adenoma pathway) between men and women.2 Also,
men have more comorbidity from other serious health
problems than women at this age, and it has been specu-
lated that it may lead to differences in cause of death
coding between men and women. This was not the case
in our material, however.
We found a substantial difference in uptake between
males (62%) and females (76%). It is obvious that par-
ticipation is differently selective in men and in women.
We have earlier reported, for example, that marital
status was of high importance in uptake, especially in
men; married men participate more often than those
who are single.39 However, this difference in uptake
should increase rather than account for the difference
in effect by gender. The difference in the CRC mortality
effect between males and females highlights the need
for a reanalysis with longer follow-up.
We did not ﬁnd any effect in a RHS study of FOBT
screening on CRC mortality. The substantial effect differ-
ence between males and females is inconsistent with the
evidence from randomised clinical trials and with the
recommendations of several international organisations.
Even though our ﬁndings are inconclusive, they high-
light the importance of randomised evaluation when
new health policies are implemented.
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